CHOKSI.BO Stock Plunges 14.5% on BSE; Medical Imaging Firm Faces Pressure

CHOKSI.BO stock tumbled 14.49% to close at INR 159.90 on the BSE today, marking a significant selloff in Choksi Imaging Limited shares. The medical imaging and healthcare equipment manufacturer saw its stock decline by INR 27.10 from the previous close of INR 187.00. Trading volume remained subdued at 4,581 shares, below the average of 5,480. The company, headquartered in Silvassa and founded in 1992, manufactures x-ray films, coronary stents, and non-destructive testing equipment for the healthcare industry. This sharp decline reflects broader market pressure on the medical specialties sector.

CHOKSI.BO Stock Price Action and Market Performance

CHOKSI.BO stock opened at INR 159.90 and remained flat throughout the session, with both day high and day low at the same level. The stock has retreated significantly from its 52-week high of INR 212.90, now trading 24.9% below that peak. However, it remains well above the 52-week low of INR 70.25, showing some resilience from extreme lows. The market capitalization stands at INR 959.50 crore with 5.70 million shares outstanding. The 50-day moving average sits at INR 145.42, while the 200-day average is INR 114.32, indicating the stock trades above longer-term support levels despite today’s sharp decline.

Valuation Metrics and Financial Health Assessment

CHOKSI.BO trades at a PE ratio of 18.58, suggesting moderate valuation relative to earnings. The price-to-book ratio stands at 2.45, indicating the stock trades at a premium to book value. Earnings per share (EPS) is INR 9.06, with the company generating INR 87.05 in revenue per share. The current ratio of 5.03 demonstrates strong liquidity and working capital of INR 241.29 crore. Debt-to-equity ratio is low at 0.078, reflecting conservative leverage. However, the company shows zero operating and free cash flow per share, which raises concerns about cash generation despite solid balance sheet metrics.

Technical Indicators Signal Mixed Momentum

The RSI reading of 56.58 suggests the stock is neither overbought nor oversold, sitting near neutral territory. MACD shows positive momentum with a value of 10.23 above the signal line of 6.35, though the histogram of 3.88 indicates weakening momentum. The ADX of 29.97 confirms a strong downtrend is in place. Bollinger Bands show the stock trading between 111.07 (lower) and 190.42 (upper), with the middle band at 150.75. The Stochastic oscillator reads 68.22 (%K) and 78.79 (%D), suggesting potential overbought conditions in the short term despite today’s decline.

Market Sentiment and Trading Activity

Trading activity remains subdued with volume at 4,581 shares, representing 83.6% of average volume. The Money Flow Index (MFI) of 49.24 indicates balanced buying and selling pressure. On-Balance Volume (OBV) stands at 29,440, reflecting cumulative trading sentiment. The Rate of Change (ROC) shows 27.50% momentum, suggesting underlying strength despite the price decline. The Awesome Oscillator reading of 29.96 indicates positive momentum in the broader market context. However, the combination of low volume and sharp price decline suggests institutional or large block selling rather than broad-based retail liquidation.

Meyka AI Rating and Forecast Outlook

Meyka AI rates CHOKSI.BO with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s strong balance sheet and moderate valuation support the neutral stance. Meyka AI’s forecast model projects the stock at INR 137.08 for the next 12 months, implying 14.3% downside from current levels. However, the five-year forecast of INR 236.94 suggests potential recovery and long-term value creation. These grades and forecasts are not guaranteed and we are not financial advisors.

Healthcare Sector Context and Competitive Landscape

Choksi Imaging operates in the Medical – Specialties industry within the Healthcare sector, which has a market cap of INR 57 trillion. The sector shows an average PE of 38.98 and ROE of 14.18%, while CHOKSI.BO’s metrics are more conservative. Recent industry developments include Nanox signing a deal for 300 imaging systems, highlighting competitive pressures in medical imaging. The company’s focus on x-ray films and coronary stents positions it in a mature segment facing digital transformation. Track CHOKSI.BO on Meyka for real-time updates on this healthcare equipment manufacturer.

Final Thoughts

CHOKSI.BO stock’s 14.49% decline to INR 159.90 reflects significant selling pressure in the medical imaging sector today. While the company maintains a solid balance sheet with strong liquidity and low debt, the sharp price drop raises questions about near-term sentiment and market expectations. The Meyka AI B-grade rating suggests holding rather than panic selling, though the 12-month forecast of INR 137.08 indicates further downside risk. Investors should monitor quarterly earnings, cash flow generation, and competitive positioning in the evolving healthcare equipment market. The stock’s valuation remains reasonable at 18.58x PE, but execution on revenue growth and profitability will determine whether this decline represents a buying opportunity or signals deeper structural challenges. Conservative investors may wait for stabilization before adding positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.